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Abstract
Background: Food hypersensitivity is a prevalent condition with poorly characterized underlying mechanisms. In the 
present pilot study we investigated effects of seal oil and soy oil on meal-induced symptoms and gastric accommodation in 
patients with subjective food hypersensitivity (FH). Single dose experiment: On three consecutive days, 10 mL of seal oil, 
soy oil, or saline were randomly administered into the duodenum of 10 patients with subjective FH and 10 healthy volunteers 
through a nasoduodenal feeding tube 10–20 minutes before the ingestion of a test meal. Short-term treatment study: 24 patients 
with subjective FH were randomly allocated to 10 days’ treatment with either 10 mL of seal or soy oil, self-administrated 
through an indwelling nasoduodenal feeding tube, 3 times daily. In both experiments meal-induced abdominal symptoms 
and gastric accommodation were measured by visual analogue scales and external ultrasound respectively.
Results: Symptoms and gastric accommodation were not signifi cantly infl uenced by single doses of seal or soy oil. When 
given daily for 10 days, seal oil, but not soy oil, reduced total symptom scores signifi cantly (P = 0.03). The symptomatic 
improvement was not associated with improvements in gastric accommodation. 
Conclusion: Daily administration of seal oil may benefi t patients with subjective FH. The benefi cial effect of seal oil in 
patients with subjective FH can not be ascribed to improved gastric accommodation.
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Background
Food hypersensitivity (FH) is a prevalent condition. In the general population, the prevalence is estimated 
around 25%, whereas in patients with functional gastrointestinal disorders, the prevalence is at least 
50% (O’Leary and Shanahan, 2002; Asero et al. 2007). The diagnosis of FH is based on the patients’ 
self-attribution of their symptoms to adverse reactions to food (Arslan et al. 2004b; Zar et al. 2002), 
thus including both allergic (IgE-mediated or non-IgE-mediated food allergy) and non-allergic reactions 
(non-allergic food hypersensitivity) (Johansson et al. 2001). The condition is associated with a high 
prevalence of psychiatric symptoms, poor quality of life and several (extraintestinal) subjective health 
complaints (Arslan et al. 2004b; Lind et al. 2005). Self-reported FH, which after relevant clinical 
examinations remains without any recognised organic or immunological explanation, is in this paper 
denoted subjective FH, as previously described (Arslan et al. 2004b).
Most patients with FH have symptoms of irritable bowel syndrome (IBS) (Arslan et al. 2004b), 
which are known to be associated with heightened perception of visceral stimuli (visceral hypersensitivity) 
(Aziz, 2006). Although psychological factors are strongly implicated (Aziz, 2006), the symptoms may 
be exacerbated and even reproduced by the administration of lipids (Feinle et al. 2001; Simren et al. 
2007), meat soup (Hjelland et al. 2004), lactulose (Morken et al. 2007) and exogenous prostaglandin 
(Rask-Madsen and Bukhave, 1979). How psychological factors and food or food ingredients interact 
and evoke IBS-like symptoms in these patients are the subject of much speculation (Akiho 
et al. 2007).
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Long chain polyunsaturated fatty acids 
(LCPUFA) have a range of different effects in the 
human body. When administered into the duodenum, 
they are known to affect various stomach motor 
functions (Feinle et al. 2001). Thus, in a recent study 
we showed that duodenal infusion of fat based on 
soy oil, relaxed the stiff proximal stomach and 
improved gastric accommodation to a test meal in 
patients with functional dyspepsia (Lunding et al. 
2006). Clinically more important might be the effects 
of long-term administration of LCPUFA on meta-
bolic and inflammatory conditions (Gil, 2002). 
Although a long-term administration strategy is 
normally applied, we found that short-term (10 days’) 
duodenal administration of seal oil markedly attenu-
ated joint pains in patients with infl ammatory bowel 
disease (IBD) (Bjørkkjær et al. 2004).
Seal oil shares many of the characteristics of 
fi sh oils, e.g. relatively high content of long chain 
n-3 PUFA (i.e. 20  carbon atoms long). In veg-
etable oils n-3 PUFA are present as α-linolenic acid 
(ALA; 18:3n-3), though the amount differs between 
oils. The main fatty acid in many vegetable oils is 
the n-6 PUFA linoleic acid (LA; 18:2n-6). ALA 
and LA are both essential fatty acids and precursors 
for the endogenously synthesised LCPUFA eicos-
apentaenoic acid (EPA; 20:5n-3) and arachidonic 
acid (AA; 20:4n-6), respectively. However, the 
capacity in humans to convert ALA to EPA, and 
especially DHA, is limited (Burdge et al. 2007). 
The n-3 PUFA in fi sh oil are mainly located in sn-2 
position of the triacylglycerol (TAG) molecule, 
while almost exclusively in sn-1 or sn-3 position 
in TAG from seal oil (Brockerhoff et al. 1968; 
Yoshida et al. 1996). The impact of the positional 
distribution of FA on the backbone of the TAG 
from marine oils, on absorption, incorporation and 
utilization is not clear (Osaki et al. 2005). However, 
the different fatty acid profi les of marine oils and 
vegetable oils may have important implications for 
the amount and type of free fatty acids released by 
pancreatic lipase in the gut, and by lipoprotein 
lipase throughout circulation, and thus provides 
different precursors for further metabolism.
The present pilot study includes one single dose 
experiment and one short-term treatment study. The 
single dose experiment was performed to test whether 
single doses of seal oil or soy oil administered into 
the duodenum would differentially infl uence the 
response to a subsequent meal. The short-term 
treatment study was executed to characterize 
potential treatment effects of the oils in patients 
with food hypersensitivity. In an attempt to elucidate 
a possible mechanism of action, gastric accom-
modation in response to the meal was measured 
using non-invasive external ultrasonography.
Materials and Methods
Patients
Patients with various unexplained abdominal symp-
toms including dyspepsia, pain, bloating, nausea, 
vomiting and disturbed bowel habits were included 
in the study provided they self-attributed their 
complaints to food intolerance (here denoted self-
reported FH). The clinical examination included a 
detailed medical history, physical examination, and 
routine laboratory tests in addition to skin-prick test 
(SPT), serum total-and food-specific IgE, and 
double-blind placebo-controlled food-challenge 
(DBPCFC). Patients with clear IgE-mediated food 
allergy and pregnant or lactating women were 
excluded. Gastroscopy including biopsies from the 
stomach and the duodenum was performed to 
exclude peptic ulcer, Helicobacter pylori infection 
and coeliac disease. An oral lactose tolerance test 
analysing blood glucose response was performed 
to exclude lactose malabsorption. Intestinal perme-
ability and calprotectin in gut lavage fl uid were 
examined to exclude IBD (Arslan et al. 2004a).
Single dose experiment 
Ten female patients (range 28–82 years, mean age 
49 years) with subjective FH. The response of the 
patients was compared to that of 10 healthy vol-
unteers (4 females and 6 males, range 23–56 years, 
mean age 31 years).
Short-term treatment study 
Twenty-four patients (22 females and 2 males, 
range 24–80 years, mean age 43 years) with sub-
jective FH were randomly allocated to short-term 
treatment with either seal oil (n = 12; 11 females 
and 1 male, mean age 45 years) or soy oil (n = 12; 
11 females and 1 male, mean age 41 years).
Experimental oils
The refi ned seal oil (Rieber Skinn A/S, Bergen, 
Norway) was from harp seal (Phagophilus 
groenlandicus), as specifi ed previously (Madland 
et al. 2006). The soy oil was commercially 
available, produced by Mills DA (Oslo, Norway). 
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In the single dose experiment, 10 mL seal oil or 
soy oil or saline solution was given per day (for 
3 days). Thus the participants received about 0.8 g 
of EPA, 0.4 g docosapentaenoic acid (DPA), and 
0.9 g of docosahexaenoic acid (DHA) from the 
seal oil per day. From the 10 mL of soy oil, the 
participants received about 5.0 g LA.
In the short-term treatment study, the partici-
pants self-administered 10 mL seal or soy oil three 
times daily for 10 days, resulting in a daily intake 
of approximately 2.4 g EPA, 1.1 g DPA and 2.6 g 
DHA, i.e. 6.1 g of n-3 LCPUFA from seal oil or 
15.0 g n-6 LA from soy oil per day. In both exper-
iments, the participants were blinded regarding the 
administered solutions and there were no taste or 
smell or known side effects that could identify the 
specifi c treatment.
Meal induced symptoms
As in several prior studies (Gilja et al. 2007) we 
applied a commercial meat soup (Toro® clear meat 
soup, Rieber and Søn A/S, Bergen, Norway) for 
symptom provocation and evaluation of gastric 
accommodation. At each experiment, the subjects 
drank during 4 min 500 mL of the soup containing 
1.8 g protein, 0.9 g bovine fat, 1.1 g carbohydrate 
and 0.2 g non-soluble seasoning (20 kcal totally). 
Beforehand, the soup was boiled and then cooled 
to 37 ºC. In previous studies this soup meal induced 
fed state motility with approximately 3 antral con-
tractions per min in over 85% of patients and 
controls (Gilja et al. 1995).
The participants were asked to score the 
meal-induced symptoms on a 100 millimetre visual 
analogue scale (VAS), where zero denotes absence 
of symptoms and 100 denotes excruciating 
symptoms. This Norwegian version of VAS has 
previously been validated in terms of reliability, 
validity and sensitivity (NRRK).
Ultrasonography
Two-dimensional (2D) ultrasound images were 
obtained using a sector scanner (System Five, GE 
Vingmed Ultrasound, Horten, Norway) with a 
4.4–5.0 MHz curvilinear transducer. The partici-
pants were scanned while sitting in a wooden chair, 
leaning slightly backwards with an angle of 120º 
between the thighs and the spine. Using the method 
of Gilja et al., three different ultrasonographic 
measures were applied at each recording time: 
proximal gastric area, frontal diameter and antral 
area (Gilja et al. 1995; Gilja et al. 2007). The 
measures were traced twice and the average result 
recorded. All sonographic examinations and mea-
surements were performed by one of the authors 
(G.A.L).
Experimental Procedure
Single dose experiment 
In random order, each participant was examined 
on three consecutive afternoons after fasting from 
breakfast. By aid of fl uoroscopy and a stylet, a 
thin nasoduodenal tube (Freka® Feeding Tube, 
Fresenius Kabi, GmbH, Germany) was positioned 
with its tip to the mid duodenum. The participants 
kept the tube inserted during the entire trial period. 
The study design is schematically outlined in 
Figure 1A. The administrations of oils or saline 
were performed slowly to prevent arousal of symp-
toms from −10 to 0 minutes, and the soup meal 
was ingested 10 minutes thereafter during 
4 minutes. The abdominal symptoms (epigastric 
pain, nausea and fullness) were recorded at −10 and 
0 minutes, and postprandially, at 14 and 24 minutes. 
The ultrasound scannings were performed at the 
same intervals.
Short-term treatment study 
Patients were randomly allocated to short-term 
duodenal treatment with either seal oil (n = 12) or 
soy oil (n = 12). 10 mL seal or soy oil was self-
administered through the indwelling nasoduodenal 
tube (described above) before meals, 3 times daily 
for 10 days. Before and after 10 days oil adminis-
tration, they ingested the test meal of 500 mL 
during 4 minutes, and abdominal symptoms (epi-
gastric pain, nausea, fullness, satiety and discom-
fort) were recorded at 0 and 4 minutes, and 
postprandially, at 14 and 24 minutes (Fig. 1B). 
Ultrasound scanning was performed at the same 
intervals.
Statistical analysis
Data were analysed and displayed using GraphPad 
Prism 5 (GraphPad Software Inc, San Diego, 
U.S.A). Results are presented as mean with stan-
dard error of the mean (SEM) both as time-curves 
and as area under the time-curves (area between 
curve and zero, AUC). Each symptom score was 
examined separately, but because analysis of 
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individual symptoms did not provide any additional 
information, only the sum of the scores are pre-
sented. In the single dose experiment, the three 
groups were primarily compared by ANOVA. Dif-
ferences were otherwise evaluated by paired and 
unpaired Student t-tests. P-values  0.05 were 
regarded statistically signifi cant.
Ethical approval
The protocol was approved by the Regional 
committee for human research ethics, Norway. All 
participants gave written informed consent.
Results
Most patients claimed intolerance to one or two 
food items, wheat fl our and cow’s milk being the 
food items most often reported intolerance to. All 
patients had negative biopsy results for Helico-
bacter pylori and coeliac disease and none of them 
had indication of lactose malabsorption. One 
patient in the single dose experiment and one in 
the short term treatment study had positive DBP-
CFC for wheat fl our and for egg, respectively. 
However, both patients had negative SPT and 
negative food-specifi c IgE towards the same food 
items. Hence, these two patients had non-IgE-
mediated food allergy or non-allergic food 
hypersensitivity.
Single-dose experiment
Meal-induced symptoms
As compared with saline, duodenal administration 
of seal oil or soy oil from −10 to 0 min before the 
meal did not signifi cantly infl uence the symptoms 
induced by the subsequent meal. The data obtained 
with saline, soy oil and seal oil administration where 
therefore pooled and signifi cant differences in sum 
symptom score were observed between patient 
group and control group both before and after 
administration of the meat soup meal (Fig. 2A).
Ultrasonography
As compared with saline, duodenal administration 
of seal oil or soy oil 10–20 min before the meal, 
did not signifi cantly infl uence the widths of antral 
areas after the test meal. Thus the data were pooled, 
and a signifi cantly wider postprandial antral area 
was observed in the patient group compared with 
the control group shortly after fi nishing the soup 
meal (P = 0.02) (Fig. 2B).
Short-term treatment study
Meal-induced symptoms
As compared with pre-treatment, 10 days’ admin-
istration of seal oil significantly reduced sum 
A
Saline/seal
oil/soy oil
Test meal
Test meal
Test meal
DAY 1 DAY 10
−10 0
0 4 14 24
10 14 24 min
min 0 4 14 24 min
10 days with 10 mL seal- or
soy oil 3 times per day
Symptom score, US
Symptom score, US Symptom score, US
EXAMINATION DAY 1 EXAMINATION DAY 11
B
Figure 1. Study design. Acute experiment A): Saline, seal or soy oil administered into the duodenum at −10 to 0 min. Test meal ingested at 
10 to 14 min. Symptom scores and antral diameter measured by ultrasound (US) at −10, 0, 14 and 24 min. Short-term experiment B): Two 
examinations, one at day 1 (before treatment) and one at day 11 (after treatment with seal oil or soy oil 10 ml × 3 per day administered by 
tube into the duodenum). Test meals ingested at 0 to 4 min in each of the two tests. Symptom scores and US measurements performed at 
0, 4, 14 and 24 min.
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symptom scores both before (i.e. at start of the 
meal) and after meal ingestion (Fig. 3A shows 
symptom profiles and Fig. 3B area under the 
curve). Administration of soy oil had no effect on 
symptoms (Figs. 3A–B).
Ultrasonography
The ultrasonographic measures showed no 
signifi cant effects on the size of the antral area of 
the stomach of  either seal oil or soy oil administration 
(Fig. 3C). Neither was there any signifi cant effect 
of the two treatments on the measures of the 
proximal stomach (results not shown).
Discussion
As compared with healthy volunteers, patients 
with subjective FH reported more symptoms in 
response to the ingestion of 500 mL meat soup and 
showed more antral distension immediately fol-
lowing the meal. This indication of impaired 
gastric accommodation is consistent with prior 
fi ndings in patients with functional dyspepsia 
(Hausken et al. 1993). Most of our patients had 
irritable bowel syndrome (approximately 80%) 
and some few functional dyspepsia according to 
Rome criteria (Park and Camilleri, 2006). Visceral 
hypersensitivity is common among such patients, 
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and the discomfort experienced in response to the 
ingestion of a dilute meat soup indicates indeed 
that visceral hypersensitivity is typical also for 
patients with self-reported FH and that the patients’ 
subjective FH might be less specifi c for particular 
food items than that often self-reported.
Single doses of seal oil or soy oil administered 
into the duodenum did not signifi cantly infl uence 
symptoms or gastric accommodation induced by 
our test meal. However, 10 days’ treatment 
with seal oil signifi cantly improved abdominal 
symptoms, both baseline symptoms at start of meal 
ingestion and symptoms evoked by the meal, with-
out any noticeable effect on gastric accommoda-
tion. Similarly administered soy oil had no effect 
on either symptoms or gastric accommodation.
Because duodenal administration of LCPUFA 
is supposed to relax the proximal stomach and 
improve gastric accommodation to meals, we 
anticipated that symptom improvement in response 
to seal oil administration would be associated with 
improvements in gastric accommodation. No such 
Time (min)
Time (min) Time (min)
Before After seal oil Before After soy oil
Time (min)
Meal
4
Su
m
 s
ym
pt
om
 s
co
re
VA
S 
(c
m
)
Su
m
 s
ym
pt
om
 s
co
re
 (A
U
C
)
A
Seal oil Soy oil
B
C
3
2
1
0
0
50
100
40 14
P = 0.03 P = 0.5
24
4
3
2
1
0
40 14 24
*
*
*
Before
After
Before
After
Su
m
 s
ym
pt
om
 s
co
re
 (A
U
C
)
0
50
100
A
nt
re
al
 a
re
a 
(c
m
2 )
20
15
10
5
0
-10 0 10 20
A
nt
re
al
 a
re
a 
(c
m
2 )
20
15
10
5
0
-10 0 10 20
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improvements in either proximal or distal (antral) 
gastric accommodation were seen. Hence, altered 
gastric accommodation can hardly explain the 
benefi cial symptomatic effect of seal oil.
More likely the benefi cial symptomatic effect of 
seal oil in patients with FH is a consequence of 
cyclooxygenase (COX) inhibition, a documented 
effect of long chain n-3 PUFAs (Cleland et al. 2006). 
Indeed, up-regulated intestinal COX activity has 
been reported in a mouse model of post-infectious 
IBS (Collins, 2007) and possibly also in patients 
with FH (Buisseret et al. 1978; Flatz and Lie, 1982; 
Peuhkuri et al. 1999). Buisseret et al. (Buisseret et al. 
1978) observed a marked rise in the blood and stool 
concentrations of prostaglandin E2 and F2-α after 
the ingestion of incompatible food in humans with 
FH, and Jones et al. concluded that prostaglandin 
production is an important factor in the pathogenesis 
of food intolerance in IBS (Jones et al. 1982). Even 
carbohydrate malabsortion may up-regulate prosta-
glandin production although neither acetylsalicylic 
acid nor ibuprofen treatment was able to relieve 
symptoms induced by ingestion of lactose or lactu-
lose (Flatz and Lie, 1982; Peuhkuri et al. 1999).
Our group of patients with subjective FH had 
indications of visceral hypersensitivity, a condition 
in which infl ammation may be involved as seen after 
induction of colitis in animal models (Zhou et al. 
2008). Changes in intestinal lymphocytes, eosino-
phils and mast cells are previously reported in func-
tional gastrointestinal disorders (Rothenberg and 
Cohen, 2007; Phillips et al. 1979; Park and Camilleri, 
2006). In the present study duodenal biopsies were 
taken mainly to exclude coeliac disease and gut 
lavage calprotectin was examined to exclude colitis. 
Long chain n-3 PUFAs have shown inconsistent 
(MacLean et al. 2005), but indeed some benefi cial 
effects on intestinal infl ammation (Belluzzi et al. 
1996; Brunborg et al. 2008). Moreover, we have 
previously reported reduced leucotriene B4 and 
prostaglandin E2 levels in blood following treatment 
with seal oil (Brunborg et al. 2008). Long chain 
PUFAs in seal oil could thus ameliorate symptoms 
through an anti-infl ammatory property.
Seal oil (and the more widely used fi sh oil) is 
rich in the natural COX inhibitor EPA, which 
competes with AA for the same COX enzymes. 
Also, the EPA-derived prostaglandins and leukot-
rienes are less pro-infl ammatory than those formed 
from AA. Soy oil, on the other hand, is rich in the 
n-6 PUFA LA, the precursor of AA, which is 
metabolised to pro-infl ammatory prostaglandins 
and leukotrienes. We applied a relatively high dose 
of seal oil, 10 mL three times daily. This high amount 
of oil was well tolerated with no adverse effects and 
the mode of administration secured near perfect 
compliance (according to patients’ verbal reports). 
The dose corresponds to approximately 5.4 g of n-3 
PUFAs a day, which is double the dose required for 
anti-infl ammatory effect (2.7 g of n-3 LCPUFA 
a day) (Cleland et al. 2006). When administered 
orally, anti-infl ammatory effects of n-3 PUFAs 
(as fi sh oil) are usually seen only after 2–3 months 
of treatment (Cleland et al. 2006). However, in a 
recent study, using the same mode of administration 
as here, it was observed a similarly rapid effect of 
seal oil administration, namely a profound reduction 
of IBD-related joint pain after 10 days’ treatment 
(Bjørkkjær et al. 2004). Because n-3, but not n-6, 
fatty acids are able to inhibit inducible COX activity, 
we speculate that the reported effect of seal oil on 
joint pains could be an effect of COX inhibition 
(Cleland et al. 2006).
Supporting a role of prostaglandins in FH are 
previous observations that oral administration of 
a prostaglandin analogue, misoprostol, aggravates 
functional gastrointestinal complaints (Hausken 
et al. 1990) while administration of non-steroid 
anti-infl ammatory drugs (NSAIDs), which inhibits 
the action of COX and thus prostaglandin synthesis, 
prevents diarrhoea in patients with IBS (Bukhave 
and Rask-Madsen, 1981). Prostaglandins not only 
induce increased intestinal transit and diarrhoea, 
but also affect nociception and visceral sensitivity 
(Lessof et al. 1983).
The potential usefulness of NSAIDs in patients 
with FH and IBS is seriously hampered by 
side-effects (Spiller et al. 2000; Marshall et al. 
2004), which include aggravation of mucosal 
damage and increased intestinal permeability 
(Aabakken, 1992). As a consequence, these drugs 
may deteriorate rather than improve important 
aspects of the pathophysiology of IBS. In addition 
comes the associated increased risk for cardiovas-
cular events, which are seen especially with the 
new COX-2 selective NSAIDs (Cleland et al. 
2006). In fact, marine oils abundant in EPA may 
constitute natural COX inhibitors, free of adverse 
side effects in addition to being cardioprotective 
(Cleland et al. 2006).
In spite of random allocation to the two treat-
ment arms, baseline symptom scores were some-
what higher in the seal oil group than in the soy oil 
group (P = 0.01). We cannot exclude a possible 
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infl uence of this odd result of randomization on 
the observed differences in effect of treatment. 
However our small pilot study suggests a benefi cial 
effect of seal oil administration in patients with FH. 
The encouraging result clearly warrants further 
studies, both on possible up-regulation of intestinal 
prostaglandin synthesis in FH and its possible 
treatment with naturally occurring modifi ers of 
prostaglandin synthesis.
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